MHLW Panel Designates Early Introduction for Vagus Nerve Stimulator Implant
This article was originally published in PharmAsia News
Executive SummaryThe panel for the early introduction of medical devices in high demand at the Ministry of Health, Labor and Welfare designated the implant Vagus nerve stimulator as a technology that merits early introduction and is targeted for fast track review. Imported by Japanese medical device maker Nihon Kohden, the device will be given an expedited review upon receipt of application. VNS therapy has been approved in 64 countries for use in treatment-resistant epilepsy and in treatment-resistant depression. Click here for more - Japanese language
You may also be interested in...
Biologic Exclusivity Provisions In USMCA Are Boon To Generics Industry; BIO Is 'Tremendously Worried'
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.